Filing Details

Accession Number:
0001567619-20-012820
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-02 16:15:21
Reporting Period:
2020-07-01
Accepted Time:
2020-07-02 16:15:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1692830 Satsuma Pharmaceuticals Inc. STSA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1640645 P. Thomas O'neil C/O Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard, Suite 221
South San Francisco CA 94080
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2020-07-01 300 $4.56 300 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2020-07-01 300 $25.63 0 No 4 S Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-07-01 394 $4.56 394 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2020-07-01 394 $26.70 0 No 4 S Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-07-01 306 $4.56 306 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2020-07-01 306 $27.59 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-07-01 1,000 $0.00 1,000 $4.56
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
67,340 2029-05-16 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $25.35 to $26.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. The transaction was executed in multiple trades in prices ranging from $26.40 to $27.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The transaction was executed in multiple trades in prices ranging from $27.50 to $27.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.